Literature DB >> 17070389

Alterations in nuclear structure and expression of proPSA predict differences between native Japanese and Japanese-American prostate cancer.

Robert W Veltri1, Masood A Khan, Cameron Marlow, M Craig Miller, Stephen D Mikolajczyk, Munekado Kojima, Alan W Partin, Leonard S Marks.   

Abstract

OBJECTIVES: To differentiate the benign and/or malignant epithelial cells in prostate cancer (PCa) glands of native Japanese (NJ) and Japanese-American (JA) men using biomarkers.
METHODS: Tissue microarrays from radical prostatectomy specimens of cancerous and adjacent benign areas from 25 NJ and 25 JA prostate glands were studied. Image analysis was used to quantify total prostate-specific antigen (PSA) and proPSA immunohistochemical staining, as well as the variance of several morphometric features from Feulgen-stained epithelial cell nuclei. Logistic regression analysis was applied to determine whether quantitative nuclear grade (QNG) calculations and PSA immunohistochemical staining could differentiate the two test groups.
RESULTS: The QNG model differentiated changes in the benign epithelium of the two Japanese groups with an area under the receiver operating characteristic curve of 84% and accuracy of 82% (P = 0.0001). A second QNG model differentiated changes in the malignant epithelium of the two groups with an area under the receiver operating characteristic curve of 84% and accuracy of 76% (P = 0.0023). Logistic regression models combining proPSA immunohistochemical data and QNG from either benign or malignant tissue components yielded areas under the receiver operating characteristic curve of 96% and 91% (P <0.0001) for differentiation of the JA and NJ groups, respectively.
CONCLUSIONS: Unique nuclear morphometric alterations demonstrated by QNG combined with proPSA immunohistologic localization independently predicted for significant differences between NJ and JA men with PCa. These preliminary observations indicate a basis for biologic and molecular alterations in the benign adjacent and malignant epithelium between these two groups.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17070389     DOI: 10.1016/j.urology.2006.05.008

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

1.  PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.

Authors:  Neil M Carleton; Guangjing Zhu; Mikhail Gorbounov; M Craig Miller; Kenneth J Pienta; Linda M S Resar; Robert W Veltri
Journal:  Prostate       Date:  2018-03-09       Impact factor: 4.104

2.  Characterization of RNA-Binding Motif 3 (RBM3) Protein Levels and Nuclear Architecture Changes in Aggressive and Recurrent Prostate Cancer.

Authors:  Neil M Carleton; Guangjing Zhu; M Craig Miller; Christine Davis; Prakash Kulkarni; Robert W Veltri
Journal:  Cancer Rep (Hoboken)       Date:  2020-01-29

3.  Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer.

Authors:  Danil V Makarov; Sumit Isharwal; Lori J Sokoll; Patricia Landis; Cameron Marlow; Jonathan I Epstein; Alan W Partin; H Ballentine Carter; Robert W Veltri
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

4.  High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer.

Authors:  Mikhail Gorbounov; Neil M Carleton; Rebecca J Asch-Kendrick; Lingling Xian; Lisa Rooper; Lionel Chia; Ashley Cimino-Mathews; Leslie Cope; Alan Meeker; Vered Stearns; Robert W Veltri; Young Kyung Bae; Linda M S Resar
Journal:  Breast Cancer Res Treat       Date:  2019-09-17       Impact factor: 4.624

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.